Research Article

Evaluation of Anti-Inflammatory Components of Guizhi Fuling Capsule, an Ancient Chinese Herbal Formula, in Human Umbilical Vein Endothelial Cells

Yuzhong Zheng,1 Guizhong Xin,2,3 Guowei Gong,4 Tina TX Dong,2 Ping Li,3 and Karl W. K. Tsim 2

1 School of Life Sciences and Food Technology, Hanshan Normal University, Chaozhou, Guangdong 521041, China
2 Division of Life Science and Center for Chinese Medicine, The Hong Kong University of Science and Technology, Clear Water Bay Road, Hong Kong, China
3 State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China
4 Department of Bioengineering, Zunyi Medical University, Zhuhai Campus, Zhuhai, Guangdong 519041, China

Correspondence should be addressed to Karl W. K. Tsim; botsim@ust.hk

Received 25 May 2020; Revised 28 September 2020; Accepted 7 October 2020; Published 23 October 2020

Academic Editor: Jihang Chen

Copyright © 2020 Yuzhong Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Guizhi Fuling capsule (GFC), a well-known formula composed of five medicinal herbs, is commonly prescribed to treat primary dysmenorrhea, as well as to achieve good clinical efficacy in China. However, the active components of GFC have not been identified. Here, the anti-inflammatory functions of GFC, as well as its major ingredients, were evaluated in human umbilical vein endothelial cells (HUVECs). Methods. Lipopolysaccharide (LPS) was used in HUVECs to imitate the cellular inflammation. Then, GFC-triggered mRNA expressions of cyclooxygenase-1 (COX-1) and COX-2 were determined by real-time PCR, while the expression of COX-2 protein was revealed by western blotting. Besides, nine components of GFC were evaluated for their contribution value in the anti-dysmenorrhea effects. Results. The application of GFC downregulated the mRNA expressions of COX-1 and COX-2 mRNAs. Nine major components of GFC were tested in the inflammatory system, and three compounds, including paeoniflorin, benzoylpaeoniflorin, and amygdalin, exhibited robust activation in HUVECs. The combination of paeoniflorin, benzoylpaeoniflorin, and amygdalin showed over 80% of the anti-inflammatory activation. Conclusion. Our study supports that GFC plays a promising role in anti-dysmenorrhea function by decreasing COXs’ expression. Besides, paeoniflorin, benzoylpaeoniflorin, and amygdalin could be considered as major regulators for the anti-dysmenorrhea effects of GFC.

1. Background

Dysmenorrhea, defined as difficult menstrual flow or painful menstruation, is one of the most common gynecologic complaints in young women who present to clinicians [1]. Aetiological studies display that the release of uterine prostaglandins could stimulate uterine contractions and ischemia leading to pain [2]. Prostaglandins generated from arachidonic acid are under the action of cyclooxygenase (COX) [3]. Among the isoforms of COX, COX-1 is constitutively expressed in the cells and is involved in homeostasis, whereas COX-2 is induced in response to pain and inflammation [3]. The mechanism of dysmenorrhea during menstruation is highly related to COX-2 expression, leading to an increase in prostaglandins [4]. Until now, the main drug used to treat dysmenorrhea has been nonsteroidal anti-inflammatory drugs, but may cause side effects, including problems in the digestive tract, liver, and kidney [5].

As a well-known traditional Chinese medicine (TCM) formula, Guizhi Fuling capsule (GFC) originated from Jingui Yaolue (220 AD) by Zhang Zhongjing. GFC consists of five herbs at the same proportion: Cinnamomum cassia Presl (Cinnamomi Ramulus), Poria cocos (Schw.) Wolf (Poria), Paeonia suffruticosa Andr. (Moutan Cortex),...
2. Methods

2.1. Reagents and Materials. The GFC samples were purchased from Jiangsu Kanion Pharmaceutical Co., Ltd. (Lianyungang, China). The voucher specimens of GFC were deposited in the Centre for Chinese Medicine of HKUST. The powder in the GCF was taken out and then dissolved in ddH2O. The GFC solutions were filtered using a 0.22-micron filter at 100 mg/mL, and the concentration was then confirmed by weighing the dry matter in solutions.

Paeoniflorin (>99%), benzoyl paeoniflorin (>99%), amygdalin (>99%), paeonol (>99%), cinnamaldehyde (>99%), cinnamic acid (>99%), pachymic acid (>99%), gallic acid (>99%), and benzoic acid (>99%) were obtained from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). All chemicals were dissolved in DMSO at 1 mg/mL as stock solutions.

3-(4,5-Dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), A23187, L-NAME, and BAPTA-AM (all at >98% purity) were purchased from Sigma Chemical Co. (St. Louis, MO). LY294002 was purchased from Cell Signaling Technologies (Danvers, MA). Ultrapure water was prepared from a Milli-Q purification system (Millipore, Molsheim, France). COX-2 antibody (sc1745) was purchased from Santa Cruz Biotechnology (USA). GAPDH rabbit mAb (5174S) was purchased from Cell Signaling Technology (Danvers, MA). Goat anti-rabbit IgG-HRP (sc2004) was purchased from Santa Cruz Biotechnology. All culture reagents were from Invitrogen (Carlsbad, CA). All chemicals used were of AR grade or HPLC grade.

2.2. Cell Culture. HUVEC cells, purchased from American Type Culture Collection (ATCC, Manassas, VA), were cultured on a 0.2% gelatin-coated T75 flask maintained in a culturing medium (M199) at 37°C in a water-saturated 5% CO2 incubator. The culture medium was composed of 20% fetal bovine serum, 90 mg/mL heparin sodium salt, 20 μg/mL endothelial cell growth serum (ECGS), 100 U/mL penicillin, and 100 μg/mL streptomycin. The passage 3 to 8 of HUVEC cells were treated by drugs (including activators and blockers) for 48 h. The cultures were harvested with high salt lysis buffer and centrifuged at 16,100 rpm for 10 min at 4°C. The protein was collected and subjected to SDS-PAGE analysis. The membrane-transferred proteins were incubated with anti-COX-2 antibodies (Cell Signaling) at 1:1,000 dilution at 4°C for 12 h. Following incubation in horseradish peroxidase- (HRP-) conjugated anti-rabbit secondary antibodies in 1:5,000 dilutions for 3 h at 25°C, the immune complexes were visualized by the enhanced ECL method (Amersham Biosciences). An image analyzer was used to compare the band intensities in the control and agonist-stimulated samples on the same gel.

2.3. Viability Assay of Cells. HUVEC cells were cultured and stabilized in a 96-well plate for 24 h. The series of concentrations of GFC or other chemicals were used to treat the cells for another 24 h. Then, the cell viability test was performed with 0.5 mg/mL of MTT in PBS for 3 h. After the solution was removed, the cell lysis was resuspended in DMSO and then measured at 570 nm absorbance. Finally, the cell viability was calculated based on the control.

2.4. Quantitative Real-Time PCR. After treating with GFC or chemicals, HUVEC cells were collected to analyze the mRNA expression of COX-1 and COX-2. According to the manufacturer’s instructions (Invitrogen), total RNA of HUVECs was isolated by using the TRIzol reagent and reverse transcribed into cDNAs. The mRNA expression was analyzed by real-time PCR with using the SYBR Green Master mix and ROX reference dye according to the manufacturer’s instructions (Applied Bioscience, Foster City, CA). The optimized primers were as follows: 5′-AG GAG ATG GCA GCA GAG TT-3′ and 5′-GTG GCC GTG TTG ACA ATG TT-3′ for human COX-1 (236 bp; NM_001271166.1); 5′-TGA ATG GGG TGA TGA GCA GT-3′ and 5′-GGG ATG CCA GTG ATA GAG GG-3′ for murine COX-2 (205 bp; NM_000963.3). As an internal control, GAPDH primers were 5′-CTT CCC GTT CTC TGG G-3′ and 5′-AAC GGA TTT GGC CGT ATT GG-3′ (657 bp; NR_0215885). The SYBR Green signal was detected using the Mx3000P™ Real-Time System (Agilent, Stratagene). PCR reactions were performed in triplicate for each sample, and the expression levels were normalized to a GAPDH gene. To confirm the specific amplification of PCR products, gel electrophoresis and melting curve analysis was performed.

2.5. Determination of COX-2 Protein. In 6-well plates, HUVEC cells were treated by drugs (including activators and blockers) for 48 h. The cultures were harvested with high salt lysis buffer and centrifuged at 16,100 rpm for 10 min at 4°C. The protein was collected and subjected to SDS-PAGE analysis. The membrane-transferred proteins were incubated with anti-COX-2 antibodies (Cell Signaling) at 1:1,000 dilution at 4°C for 12 h. Following incubation in horseradish peroxidase- (HRP-) conjugated anti-rabbit secondary antibodies in 1:5,000 dilutions for 3 h at 25°C, the immune complexes were visualized by the enhanced ECL method (Amersham Biosciences). An image analyzer was used to compare the band intensities in the control and agonist-stimulated samples on the same gel.

2.6. Statistical Analysis and Other Assays. Concentrations of protein were tested by Bradford’s method (Hercules, CA). Statistical tests were performed by using one-way analysis of variance. Data were expressed as mean ± SEM, n = 4 – 5. Statistically significant changes were classified as significant (*) where p < 0.05, more significant (**) where p < 0.01, and highly significant (***) where p < 0.001.

The Minimum Standards of Reporting Checklist contains details of the experimental design, statistics, and resources used in this study.
3. Results

3.1. GFC Downregulates Cyclooxygenase Expression.
Abnormal upregulation of COXs, especially COX-2, is commonly involved in several inflammation-induced diseases, e.g., dysmenorrhea [3,4]. We determined the inhibitory effects of GFC on the expression of COX-1 and COX-2 in HUVECs. Firstly, the application of GFC in HUVECs did not affect the cell viability when its dosage was lower than 100 μg/mL (Figure 1(a)), which decided a dosage range of GFC for the following experiments. GFC from 1 to 100 μg/mL was applied onto the HUVEC culture for 48 hours, which downregulated COX (COX-1 and COX-2) expressions in a dose-dependent manner. 100 μg/mL of GFC showed a maximal effect of ~80% and 60% inhibition to COX-1 and COX-2, respectively (Figure 1(b)).

In cultured HUVECs, application of lipopolysaccharide (LPS), an activator of inflammation, induced the expressions of COX-1 and COX-2 to over 6-folds (Figure 2(a)). Dexamethasone, served as a positive control of immune suppressor, sharply reduced COX-1 and COX-2 expressions to ~2-fold of the control. When the cells were treated with GFC for 48 hours after applying LPS, the mRNA expressions of COX-1 and COX-2 were inhibited in a dose-dependent manner. 100 μg/mL of GFC could obtain maximal inhibition, which decreased by 80% (Figure 2(a)). Regarding LPS-induced COX expression, the suppression of GFC was better than that of dexamethasone.

In addition, LPS also induced COX-2 protein expression in HUVECs. This induction could be suppressed by GFC. In the background, the COX-2 protein (~69 kDa) was barely detectable in HUVECs. With the treatment of LPS, the expression of COX-2 protein increased dramatically (Figure 2(b)). However, the addition of GFC could significantly reduce the LPS-induced COX-2 protein expression, as in the case of mRNA expression. Moreover, the suppression of COX-2 expression by GFC was in a dose-dependent manner. Dexamethasone served as the positive control (Figure 2(b)).

3.2. Compounds of GFC Inhibits LPS-Induced Cyclooxygenase Expression.
GFC was provided by Jiangsu Kanion Pharmaceutical Co., Ltd. We selected nine chemicals to qualify GFC, i.e., paeoniflorin, benzoylpaeoniflorin, amygdalin, paenol, cinnamic aldehyde, cinnamic acid, pachymic acid, gallic acid, and benzoic acid. The chemicals are supposed to be active ingredients, and their contents in GFC have been summarized in Table 1, according to previous publication [7,10]. Among them, the chemical contents of top four were paeoniflorin, amygdalin, paenol, and gallic acid; they were more than 0.8% in GFC. The quality of GFC exceeded the requirements as stated in Chinese Pharmacopoeia (2020).

In addition, nine selected chemicals were evaluated with the biological analyses. The cytotoxicity of all chemicals in cultures was tested. The suitable doses of two chemicals, cinnamic aldehyde and pachymic acid, were lower than 20 μM and 25 μM, respectively. The other chemicals did not affect the cell viability when their dosages were lower than 250 μM (Table 1). At the same time, the inflammatory response of all chemicals was evaluated in HUVECs. Unexpectedly, three chemicals, paeoniflorin, benzoylpaeoniflorin, and amygdalin, exhibited potential bioactivity to inhibit COX expressions. The others did not show suppression responses (data not shown). Comparing the response value of three compounds in HUVECs, the active strong-to-weak sequence was paeoniflorin > benzoylpaeoniflorin > amygdalin.

Based on the above results, we further revealed the anti-inflammatory effects of active compounds. As expected, paeoniflorin could inhibit LPS-induced COX-1 and COX-2 mRNA expressions in a dose-dependent manner; the inhibition efficiency of 10 μM paeoniflorin could reach ~80% (Figure 3(a)). Besides, paeoniflorin could decrease the quantity of LPS-induced COX-2 protein in a dose-dependent manner. The effect of paeoniflorin was similar to that of dexamethasone, which was a positive control (Figure 3(b)). Benzoylpaeoniflorin inhibits LPS-induced COX-1 and COX-2 mRNA expressions in a dose-dependent manner, and the inhibition efficiency of 10 μM could reach ~60% (Figure 4). Amygdalin inhibits LPS-induced COX-1 and COX-2 mRNA expressions in a dose-dependent manner, and the inhibition efficiency of 10 μM could reach ~50% (Figure 5).

In order to evaluate the contribution of various ingredients to GFC, the combination of paeoniflorin, benzoylpaeoniflorin, and amygdalin was applied onto the cultures. The combined rate of three chemicals was in compliance with their concentration in GFC. The 10 μg/mL of GFC should contain 2.00 μM paeoniflorin, 0.18 μM benzoylpaeoniflorin, and 0.82 μM amygdalin. We mixed paeoniflorin, benzoylpaeoniflorin, and amygdalin equally. This mixture could suppress LPS-induced COX-1 and COX-2 mRNA levels in a dose-dependent manner (Figure 6). At 3.00 μM, the effects of combination could reach ~80% of GFC’s suppression at 10 μg/mL. In other words, the contribution rate of three compounds to the anti-inflammatory functions of GFC reached at least ~80%.

4. Discussion

GFC, a well-known herbal formula, is prescribed for women’s diseases, e.g., dysmenorrhea, hysteromyoma, endometriosis, and other gynecological diseases [11]. The clinical effect of GCF is very remarkable to be used in China for over 2,000 years. The complexity of GFC of having five herbs hinders the discovery of functional mechanisms as a therapeutic agent in the disease treatment. In a previous study, a systematic approach to study herbal formulae has been successfully applied to reveal the chemical and biological assessments of Danggui Buxue Tang, Kaixin San, Fo Shou San, and Yu Ping Feng San [9,12–14]. Therefore, these approaches were applied here in GFC to uncover the clinical treatment of dysmenorrhea. The anti-inflammatory effects of GFC had been confirmed to downregulate COX expression in HUVECs. The results were consistent with the previous animal studies [8,15].
Figure 1: GFC downregulates cyclooxygenase expression in HUVECs. (a) Different amounts of GFC (0–250 μg/mL) were applied onto cultured HUVEC cells for 48 hours, and then the cell viability was determined. (b) HUVEC cells were treated with GFC (0–100 μg/mL) for 48 hours. Total RNAs were extracted and reverse transcribed to cDNA for real-time PCR analysis. The mRNA levels of COX-1 and COX-2 were determined by the Ct-value method and normalized by the mRNA level of a house-keeping gene GAPDH. Values were expressed as the percentage of control (untreated culture). Data were expressed as mean ± SEM, where n = 4; * p < 0.05; ** p < 0.001.

Figure 2: GFC inhibits LPS-induced cyclooxygenase expression. (a) Cultured HUVEC cells were pretreated with LPS (1 μg/mL) for 3 hours before the application of different GFC (0–100 μg/mL) for 48 hours. The mRNA levels of COX-1 and COX-2 were determined by the Ct-value method and were normalized by the mRNA level of GAPDH. Values were expressed as the percentage of control (untreated culture). Data were expressed as mean ± SEM, where n = 4; * p < 0.05; ** p < 0.001.

(b) The cell lysates were collected to determine the protein expressions of COX-2 (∼69kDa) using a specific antibody. Ten μM of dexamethasone (Dex) served as positive control. GAPDH (∼38kDa) served as loading control. Quantification of protein amount from the blot was calculated by using a densitometer. Values were expressed as the fold of increase to basal reading (untreated culture). Data were expressed as mean ± SEM, where n = 4; * p < 0.05; ** p < 0.001.
COX is a rate-limiting enzyme in the initial steps of prostaglandin synthesis and plays an important role during the synthesis of prostaglandins. COX-1 is distributed in the stomach, small intestine, kidney, and platelets, while COX-2, distributed only in the kidney and brain under normal circumstances, is induced by inflammation, colorectal tumor, and pain. COX-2 appeared to be involved mainly in early inflammatory processes, but COX-1 has no close relationship with the inflammation [16, 17]. Many kinds of inflammatory mediators including proinflammatory cytokines, oxygen-derived free radicals, and cells stimulate the body to produce an inflammatory response, which could induce COX-2 to express abundantly. Finally, the overexpression of COX-2 would induce synthesis and accumulation of prostaglandins and inflammatory cytokines in the damaged tissues, which subsequently produced a series of outcomes, such as local inflammation and tissue damage [18]. Paeoniflorin, benzoylpaeoniflorin, and amygdalin of

| No. | Compound                | Derivation                                      | Content in GFC (%) | Noncytotoxicity (μM) | Bioactivity in HUVEC cells |
|-----|-------------------------|-------------------------------------------------|--------------------|----------------------|---------------------------|
| 1   | Paeoniflorin            | Paeoniae Radix Alba/Moutan Cortex               | 2.25               | <1000                | +++                       |
| 2   | Benzoylpaeoniflorin     | Paeoniae Radix Alba/Moutan Cortex               | 0.28               | <500                 | ++                        |
| 3   | Amygdalin               | Persicae Semen                                 | 2.15               | <1000                | +                         |
| 4   | Paeonol                 | Paeoniae Radix Alba/Moutan Cortex               | 1.43               | <500                 |                           |
| 5   | Cinnamic aldehyde       | Cinnamomni Ramulus                             | 0.20               | <20                  | N                         |
| 6   | Cinnamic acid           | Cinnamomni Ramulus                             | 0.15               | <1000                | N                         |
| 7   | Pachymic acid           | Poria                                           | 0.08               | <25                  | N                         |
| 8   | Gallic acid             | Moutan Cortex/Persicae Semen/Paeoniae Radix Alba| 0.88               | <250                 | N                         |
| 9   | Benzoic acid            | Moutan Cortex/Paeoniae Radix Alba              | 0.12               | <500                 | N                         |

*The chemical content was cited from Zhang et al. (2015); the cytotoxicity data were expressed as the mean of n replicates (n ≥ 4). "+++" indicates that the inhibition ratio to the mRNA expression of COXs is lower than 70%. "++" indicates that the inhibition ratio is between 50% and 70%. "+" indicates that the inhibition ratio is between 30% and 50%. "N" indicates that the inhibition ratio is lower than 30%.

**Figure 3:** Paeoniflorin inhibits LPS-induced cyclooxygenase expression. (a) Cultured HUVEC cells were pretreated with LPS (1 μg/mL) for 3 hours before the application of paeoniflorin (PF; 0–10 μM) for 48 hours. The mRNA levels of COX-1 and COX-2 were determined by the Ct-value method and normalized by the mRNA level of GAPDH. (b) The cell lysates were collected to determine the protein expressions of COX-2 using a specific antibody. Ten μM of dexamethasone (Dex) served as positive control. GAPDH served as loading control. Quantification of protein amount from the blot was calculated by a densitometer. Values were expressed as the fold of increase to basal reading (untreated culture). Data were expressed as mean ± SEM, where n = 4.* p < 0.05; ** p < 0.01; *** p < 0.001.
Figure 4: Benzoylpaeoniflorin inhibits LPS-induced cyclooxygenase expression. Cultured HUVEC cells were pretreated with LPS (1 μg/mL) for 3 hours before the application of benzoylpaeoniflorin (BPF; 0–10 μM) for 48 hours. The mRNA levels of COX-1 and COX-2 were determined by the Ct-value method and normalized by the mRNA level of GAPDH. Ten μM of dexamethasone (Dex) served as positive control. Values were expressed as the fold of increase to basal reading (untreated culture). Data were expressed as mean ± SEM, where n = 4; * p < 0.05; ** p < 0.01.

|          | LPS (1 μg/mL) | Dex (10 μM) | BPF (μM) |
|----------|---------------|-------------|----------|
|          | –             | –           | –        |
|          | +             | –           | 1        |
|          | +             | –           | 3        |
|          | +             | –           | 10       |

Figure 5: Amygdalin inhibits LPS-induced cyclooxygenase expression. Cultured HUVEC cells were pretreated with LPS (1 μg/mL) for 3 hours before the application of amygdalin (AD; 0–10 μM) for 48 hours. The mRNA levels of COX-1 and COX-2 were determined by the Ct-value method and normalized by the mRNA level of GAPDH. Ten μM of dexamethasone (Dex) served as positive control. Values were expressed as the fold of increase to basal reading (untreated culture). Data were expressed as mean ± SEM, where n = 4; * p < 0.05; ** p < 0.01; *** p < 0.001.
GFC were shown to inhibit COX-2 expression in HUVECs. In parallel, paeoniflorin was shown to decrease COX-2 expression in the synovium, which was a benefit to suppress arthritis in a rat model [15, 19]. On the other hand, paeoniflorin could protect ischemia-induced brain damage by inhibiting COX-2-mediated activity in rats [20]. Overall, paeoniflorin is supposed to be a potential anti-inflammation chemical.

So far, which compound of GFC is responsible for the anti-inflammatory effect in HUVECs remains unclear and needs to be clarified in a further study. Based on Chinese Pharmacopoeia (2020), paeoniflorin, amygdalin, and paeonol are designated as markers for quantitative analysis of GFC by ultrasound-assisted extraction combined with HPLC-UV detection with isocratic elution. However, the cognition to active components in GFC still remains insufficient. We screened nine major components of GFC, and paeoniflorin, benzoylpaeoniflorin, and amygdalin were shown to contribute most of the effects of GFC in HUVECs. Benzoylpaeoniflorin, not registered in Chinese Pharmacopoeia, showed a positive effect; but its amount in GFC was much less than that of paeoniflorin and amygdalin. Therefore, the bioactivity results coincided well with the markers designated by Chinese Pharmacopoeia. Besides, GFC and its active components could be a complementary way to shed light on cardiovascular drug research.

5. Conclusions

Our study supports that GFC has a promising role in anti-dysmenorrhea function by decreasing COXs' expression. Besides, paeoniflorin, benzoylpaeoniflorin, and amygdalin could be considered as major regulators for the anti-dysmenorrhea effects of GFC.

Abbreviations

COX: Cyclooxygenase
Dex: Dexamethasone
ECGS: Endothelial cell growth serum
GFC: Guizhi Fuling capsule
HUVECs: Human umbilical vein endothelial cells
LPS: Lipopolysaccharide
TCM: Traditional Chinese Medicine.

Data Availability

All data generated or analyzed during this study are included in this published article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

YZZ participated in the design of the study and drafted the manuscript. GZX participated in the data analysis and drafted the manuscript. AGWG participated in data extraction and assessed study quality. TTXD participated in search of the literature and extracted data. PL participated in the modification of the manuscript. KWKT conceived the study and codeveloped the full text of the review. All authors read and approved the final manuscript. Yuzhong Zheng and Gui Zhong Xin contributed equally to this work.

Acknowledgments

This study was supported by Research Fund for the Doctoral Program of Higher Education and Research Grants Council Earmarked Research Grants (20130996140001, GRF (M-HKUST604/13, 663012, and 662713), Hong Kong Research Grants Council Theme-Based Research Scheme (T13-607/12R and TUYF15SC01), The Hong Kong Jockey Club Charities Trust (HKJCCT12SC01), Foundation of the Awareness of Nature (TAON12SC01; JCY120160229205726699 to Prof. Karl Tsim; JCY120160229205812004 to Dr. Tina Dong; and JCY120160229210027564 to Dr. Huai You Wang), Science and Technology Planning Project of Guangdong (2014A020221058 and 2018A030307074) to Dr. Zheng, and
Research Fund of the Guizhou Science and Technology Foundation of China (no. QKHJC[2020]1Y377) to Dr. Gong.

References

[1] J. R. Klein and I. F. Litt, “Epidemiology of adolescent dysmenorrhea,” *Pediatrics*, vol. 68, no. 5, pp. 661–664, 1981.

[2] M. A. Lumsden, R. W. Kelly, and D. T. Baird, “Primary dysmenorrhea: the importance of both prostaglandins E2 and F2alpha,” *BJOG: An International Journal of Obstetrics and Gynaecology*, vol. 90, no. 12, pp. 1135–1140, 1983.

[3] J. R. Vane, Y. S. Bakhle, and K. M. Botting, “Cyclooxygenases 1 and 2,” *Annual Review of Pharmacology and Toxicology*, vol. 38, no. 1, pp. 97–120, 1998.

[4] H.-P. Zahradnik, A. Hanjalic-Beck, and K. Groth, “Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review,” *Contraception*, vol. 81, no. 3, pp. 185–196, 2010.

[5] G. Lefebvre, O. Pinsonneault, V. Antao et al., “Primary dysmenorrheal consensus guideline,” *Journal of Obstetrics and Gynaecology Canada*, vol. 27, no. 12, pp. 1117–1146, 2005.

[6] Y. J. Liu, W. Xiao, Z. Zhang et al., “Effects and safety of varying doses of Guizhi fuling capsule in patients with primary dysmenorrheal: multi-center, randomized, double-blind, placebo-controlled clinical study,” *China Journal of Chinese Materia Medica*, vol. 38, pp. 2019–2022, 2013.

[7] Z. Z. Zhang, X. Z. Zhang, N. Li et al., “Study on anti-inflammation effect and involved mechanism of Guizhi fuling capsule and its active complex,” *China Journal of Chinese Materia Medica*, vol. 40, no. 6, pp. 993–998, 2015.

[8] S. Lan, L. Liu, S. Zong et al., “Traditional Chinese medicine Guizhi fuling capsule used for therapy of dysmenorrhea via attenuating uterus contraction,” *Journal of Ethnopharmacology*, vol. 191, pp. 273–279, 2016.

[9] C. W. C. Bi, L. Xu, X. Y Tian et al., “Fo Shou San, an ancient Chinese herbal decoction, protects endothelial function through increasing endothelial nitric oxide synthase activity,” *PLoS One*, vol. 7, p. e49701, 2012.

[10] J.-H. Kim, C.-S. Seo, and H.-K. Shin, “Development of validated determination of the eleven marker compounds in Gyejibokryeong-hwan for the quality assessment using HPLC analysis,” *Archives of Pharmacal Research*, vol. 38, no. 1, pp. 52–62, 2015.

[11] Y. Sui, L.-S. Zhao, Z.-Z. Wang, Y.-T. Zhao, W. Xiao, and Z.-L. Xiong, “Simultaneous determination of seven bioactive components in Guizhi fuling capsule by microwave-assisted extraction combined with ultra performance liquid chromatography tandem mass spectrometry,” *Natural Product Research*, vol. 30, no. 3, pp. 354–357, 2016.

[12] K. Y. Z. Zheng, R. C. Y. Choi, H. Q. H. Xie et al., “The expression of erythropoietin triggered by danggui buxue tang, a Chinese herbal decoction prepared from radix astragali and radix angelicae sinensis, is mediated by the hypoxia-inducible factor in cultured HEK293T cells,” *Journal of Ethnopharmacology*, vol. 132, no. 1, pp. 259–267, 2010.

[13] K. Y. Zhu, Q. Fu, H. Q. Xie et al., “Quality assessment of a formulated Chinese herbal decoction, Kaixinsan, by using rapid resolution liquid chromatography coupled with mass spectrometry: a chemical evaluation of different historical formulae,” *Journal of Separation Science*, vol. 33, no. 23-24, pp. 3666–3674, 2010.

[14] C. Y. Du, R. C. Choi, T. T. Dong, D. T. Lau, and K. W. Tsim, “Yu Ping Feng San, an ancient Chinese herbal decoction, regulates the expression of inducible nitric oxide synthase and cyclooxygenase-2 and the activity of intestinal alkaline phosphatase in cultures,” *PLoS One*, vol. 9, no. 6, p. e100382, 2014.

[15] Z. Jia and J. He, “Paeoniflorin ameliorates rheumatoid arthritis in rat models through oxidative stress, inflammation and cyclooxygenase 2,” *Experimental and Therapeutic Medicine*, vol. 11, no. 2, pp. 655–659, 2016.

[16] K. Mederle, M. Meurer, H. Castrop, and K. Hocherl, “Inhibition of COX-1 attenuates the formation of thromboxane A2 and ameliorates the acute decrease in glomerular filtration rate in endotoxemic mice,” *American Journal of Physiology- Renal Physiology*, vol. 309, no. 4, pp. F332–F340, 2015.

[17] Y. J. Choi, W.-S. Lee, E.-G. Lee, M.-S. Sung, and W.-H. Yoo, “Sulforaphane inhibits IL-1β-induced proliferation of rheumatoid arthritis synovial fibroblasts and the production of MMPs, COX-2, and PGE2,” *Inflammation*, vol. 37, no. 5, pp. 1496–1503, 2014.

[18] R. N. Dubois, S. B. Abramson, L. Crofford et al., “Cyclooxygenase in biology and disease,” *The FASEB Journal*, vol. 12, no. 12, pp. 1063–1073, 1998.

[19] Y.-Q. Zheng, W. Wei, L. Zhu, and J.-X. Liu, “Effects and mechanisms of paeoniflorin, a bioactive glucoside from paony root, on adjuvant arthritis in rats,” *Inflammation Research*, vol. 56, no. 5, pp. 182–188, 2007.

[20] R. B. Guo, G. F. Wang, A. P. Zhao, J. Gu, X. L. Sun, and G. Hu, “Paeoniflorin protects against ischemia-induced brain damages in rats via inhibiting MAPKs/NF-κB-mediated inflammatory responses,” *PLoS One*, vol. 7, no. 11, p. e49701, 2012.